Pre-existing mutations in the rilpivirine Phase III trials ECHO and THRIVE: Prevalence and impact on virological response

Antiviral Therapy

Volumn 18, Issue 2, 2013, Pages 253-256

  Vingerhoets, Johan ^a   Rimsky, Laurence ^a   Van Eygen, Veerle ^a   Nijs, Steven ^a   Vanveggel, Simon ^a   Boven, Katia ^a   Picchio, Gaston ^b  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE PLUS ZIDOVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RILPIVIRINE; TENOFOVIR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG EFFICACY; GENETIC SCREENING; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MUTATION RATE; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; NITRILES; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84875676262     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2358     Document Type: Article

References (15)

1. Tibotec, Inc. EDURANT® (rilpivirine). (Updated May 2011. Accessed 3 February 2012.) Available from http://www.accessdata.fda.gov/drugsatfda-docs/ label/2011/202022s000lbl.pdf
2. Cohen CJ, Andrade-Villanueva J, Clotet B, et al. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatmentnaive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 2011; 378:229-237.
3. Molina JM, Cahn P, Grinsztejn B, et al. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatmentnaive adults infected with HIV-1 (ECHO): a Phase 3 randomised double-blind active-controlled trial. Lancet 2011; 378:238-246.
4. Cohen CJ, Molina JM, Cassetti I, et al. Pooled week 96 eficacy, resistance and safety results from the double-blind, randomised, Phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naive, HIV-1-infected adults. 6th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 17-20 July 2011, Rome, Italy. Abstract TULBPE032.
5. Delaugerre C, Rohban R, Simon A, et al. Resistance proile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001; 65:445-448.
6. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: fall 2006. Top HIV Med 2006; 14:125-130.
7. Tambuyzer L, Azijn H, Rimsky LT, et al. Compilation and prevalence of mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2009; 14:103-109.
8. Vingerhoets J, Tambuyzer L, Azijn H, et al. Resistance proile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies. AIDS 2010; 24:503-514.
9. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008; 16:138-145.
10. Pozniak AL, Morales-Ramirez J, Katabira E, et al. Eficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a Phase IIb randomized trial. AIDS 2010; 24:55-65.
11. Dean J, Ta Thi TH, Dunford L, et al. Prevalence of HIV type 1 antiretroviral drug resistance mutations in Vietnam: a multicenter study. AIDS Res Hum Retroviruses 2011; 27:797-801.
12. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009; 48:239-247.
13. Van Laethem K, De Munter P, Schrooten Y, et al. No response to irst-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on eficacy of low genetic barrier drugs. J Clin Virol 2007; 39:43-47.
14. Stanford University. Stanford University HIV Drug Resistance Database. (Accessed 3 February 2012.) Available from http://hivdb.stanford.edu/
15. Mackie N, Garvey L, Geretti AM, et al. Predicting NNRTI resistance: do polymorphisms matter? 18th Conference on Retroviruses and Opportunistic Infections. 27 February-2 March 2011, Boston, MA, USA. Abstract 595.